CTMX vs. SELB, DRRX, RDHL, CNCE, KALV, CYRX, CDMO, IGMS, TRDA, and SIGA
Should you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Selecta Biosciences (SELB), DURECT (DRRX), RedHill Biopharma (RDHL), Concert Pharmaceuticals (CNCE), KalVista Pharmaceuticals (KALV), Cryoport (CYRX), Avid Bioservices (CDMO), IGM Biosciences (IGMS), Entrada Therapeutics (TRDA), and SIGA Technologies (SIGA).
Selecta Biosciences (NASDAQ:SELB) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.
CytomX Therapeutics has a net margin of 13.87% compared to CytomX Therapeutics' net margin of -72.04%. Selecta Biosciences' return on equity of -30.70% beat CytomX Therapeutics' return on equity.
Selecta Biosciences has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.
In the previous week, CytomX Therapeutics had 9 more articles in the media than Selecta Biosciences. MarketBeat recorded 9 mentions for CytomX Therapeutics and 0 mentions for Selecta Biosciences. Selecta Biosciences' average media sentiment score of 0.49 beat CytomX Therapeutics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media.
Selecta Biosciences has higher revenue and earnings than CytomX Therapeutics. Selecta Biosciences is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.
Selecta Biosciences presently has a consensus target price of $2.80, indicating a potential upside of ∞. CytomX Therapeutics has a consensus target price of $5.77, indicating a potential upside of 239.56%. Given CytomX Therapeutics' higher possible upside, equities research analysts plainly believe Selecta Biosciences is more favorable than CytomX Therapeutics.
CytomX Therapeutics received 41 more outperform votes than Selecta Biosciences when rated by MarketBeat users. Likewise, 66.07% of users gave CytomX Therapeutics an outperform vote while only 57.47% of users gave Selecta Biosciences an outperform vote.
42.0% of Selecta Biosciences shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 31.2% of Selecta Biosciences shares are owned by company insiders. Comparatively, 7.0% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
CytomX Therapeutics beats Selecta Biosciences on 11 of the 15 factors compared between the two stocks.
Get CytomX Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CytomX Therapeutics Competitors List
Related Companies and Tools
